Business & Regulation

Why some stakeholders are not happy about the FDA’s removal of tirzepatide from the drug shortage list.

The highlights of the trade show and its conference agenda - day 3

The highlights of the trade show and its conference agenda - day 2

The highlights of the trade show and its conference agenda - day 1

Here’s a look at recent violations cited in FDA Warning Letters: fly pupae, cross contamination, trial dosing errors, and more.

Michael Altorfer, CEO, Swiss Biotech Association, gives his view on the future of drug development.

We asked over 100 industry professionals for their views on the future of the pharma and biopharma industries.

Biopharma companies procrastinating on sustainability measures risk falling behind, according to Cytiva’ Global Biopharma Sustainability Review.

A look back at some of the most inspiring quotes from our interviews.

AstraZeneca’s FluMist is the first flu vaccine to be approved for self-administration.